C-jun: pharmaceutical target for DNAzyme therapy of multiple pathologies

Area of Science:

• Molecular biology
• Biotechnology
• Therapeutics

Background:

• DNAzymes are catalytic DNA molecules capable of specific mRNA cleavage.
• The basic region-leucine zipper protein c-Jun is implicated in various diseases, including cancer and inflammation.
• Targeting c-Jun offers a potential therapeutic strategy.

Purpose of the Study:

• To review the therapeutic potential of DNAzymes targeting c-Jun.
• To present new data on a c-Jun DNAzyme's efficacy against cancer cells.
• To highlight the role of c-Jun downregulation in cancer cell apoptosis.

Main Methods:

• Literature review of DNAzyme applications in disease therapy.
• In vitro testing of a c-Jun DNAzyme against various cancer cell lines.
• Analysis of c-Jun protein levels and cancer cell viability post-treatment.

Main Results:

• c-Jun DNAzymes have shown efficacy in preclinical models of cancer, ocular neovascularisation, arterial thickening, acute inflammation, and rheumatoid arthritis.
• The tested c-Jun DNAzyme demonstrated activity against a panel of cancer cells.
• Downregulation of c-Jun led to apoptotic cell death in cancer cells.

Conclusions:

• DNAzymes targeting c-Jun represent a promising therapeutic approach.
• The c-Jun DNAzyme shows potential as a lead candidate for developing novel DNAzyme therapeutics.
• Further research is warranted to explore the full therapeutic potential of c-Jun DNAzymes.